Anaxsys Technology Ltd Asthma Monitoring Device

Anaxsys Technology Ltd 哮喘监测设备

• 批准号: 700503
• 金额: $ 3万
• 依托单位: ANAXSYS TECHNOLOGY LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Market
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=700503
• 关键词: Anaxsys; Technology; Ltd; Asthma; Monitoring

Every 10 seconds someone in the UK is having a potentially life threatening asthma attack.Asthma attacks kill 3 people each day and the UK has amongst the highest death rates fromasthma in Europe from a patient population of approximately 5.4 million.Most tragicallymany of these deaths and serious attacks could be prevented, since effective drugs areavailable to control the condition.Managing asthma is complex since patients are not constantly symptomatic and managementplans include increasing medication dose during symptomatic periods and reducing the doseto baseline levels following resolution of exacerbations. Patients often become symptomaticgradually, accommodate deterioration and do not increase steroid dose early enough to avoida crisis attack.Anaxsys has developed proprietary sensor technology that detects the moisture in breath anduses the shape of the breath profile to detect asthma.The objective of this project is to research the market for a monitoring device that can helppatients to improve the management of their asthma, leading to a reduction in asthma attacksthat lead to hospitalisations and increased mortality. The study seeks to understand the issuessurrounding patient monitoring of asthma, including compliance issues and to establish ifdevice design can improve compliance.Questions that the market research will address include:Do GPs see a place for a monitoring device that detects changes in asthma status and providesguidance for patients (via a traffic light system?) to titrate their steroid dose?Can patients use the Anaxsys device and see a potential benefit for the control of their asthma.Which features are desired by patients from a series of device options.We will also seek views from GPs, patients and NHS purchasing on potential pricing for thedevice and explore the potential cost benefit to the NHS.

每10秒，英国就有人发生可能危及生命的哮喘发作。哮喘发作每天导致3人死亡，英国是欧洲哮喘死亡率最高的国家之一，患者人数约为540万。最悲惨的是，其中许多死亡和严重发作是可以预防的，因为有有效的药物可以控制病情。管理哮喘是复杂的，因为患者并不总是有症状，管理计划包括在有症状期间增加药物剂量，在病情加重缓解后将剂量降至基线水平。患者通常会逐渐变得焦虑，适应恶化，并且没有及时增加类固醇剂量以避免危机发作。Anaxsys开发了专有的传感器技术，可以检测呼吸中的水分，并使用呼吸轮廓的形状来检测哮喘。该项目的目的是研究市场上的监测设备，可以帮助患者改善对哮喘的管理，导致哮喘发作减少，导致住院和死亡率增加。该研究旨在了解哮喘患者监测的问题，包括依从性问题，并确定设备设计是否可以提高依从性。市场研究将解决的问题包括：全科医生是否看到了监测设备的位置，可以检测哮喘状态的变化并为患者提供指导（通过交通灯系统）？调整类固醇剂量吗患者是否可以使用Anaxsys设备并看到其哮喘控制的潜在益处。患者希望从一系列设备选项中获得哪些功能。我们还将征求全科医生，患者和NHS采购对设备潜在定价的意见，并探索NHS的潜在成本效益。